



Theravance

Facsimile Cover Sheet

To: Office of Initial Preliminary Examination's
Filing Receipt Corrections
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Fax: (703) 746-9195

From: Joyce Cohen, Legal Dept.
Company: Theravance, Inc.
901 Gateway Boulevard
South San Francisco, California 94080 USA

Telephone: (650) 808-6000
Fax: (650) 808-6078

Date: July 19, 2004
of pages: 5 pages
(including this page)

Re: U.S. Serial No. 10/825,038 Attorney Docket No.: P-022-US5
entitled: Intermediate for Preparing Glycopeptide Derivatives

OFFICIAL PAPERS

Att: Request for a Corrected Filing Receipt (2-pages)
Marked-Up Copy of Filing Receipt showing Changes) (2-pages)

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 at the facsimile number indicated below.

Dated: July 19, 2004

Facsimile Number: (703) 872-9396

746-9195 (10)

By:

Joyce G. Cohen, Reg. No. 44,622

PRIVILEGED AND CONFIDENTIAL

Notice of Confidentiality

The following transmittal contains confidential information intended exclusively for the above-named person. Use or disclosure of information transmitted in error is prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the faxed enclosures to us.

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 at the facsimile number indicated below.

Dated: July 11 2004

Facsimile Number: (703) 746-9195

By: Joyce Cohen
Joyce G. Cohen, Reg. No. 44,622

PATENT

Attorney Docket No. P-022-US5

Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Martin S. LINSELL

Application No.: 10/825,038

Filed: April 15, 2004

For: **INTERMEDIATE FOR PREPARING
GLYCOPEPTIDE DERIVATIVES**

)
)
) Group Art Unit: 1646
)
) Examiner: To be assigned
)
)
)
)

REQUEST FOR A CORRECTED FILING RECEIPT

Office of Initial Patent Examination's
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Washington, D.C. 20231

Sir:

Applicants respectfully request a Corrected Filing Receipt for the above-identified patent application.

Please correct the Filing Receipt as follows:

1. The title of the application (shown on page 2 of the Filing Receipt) should be changed:

Intermediate for Preparing Glycopeptide Derivatives
and Pharmaceutical Compositions Containing the Same

to match the application transmittal, and Preliminary Amendment filed on April 15, 2004.

A copy of the Filing Receipt with the changes noted thereon is attached.

Application No. 10/825,038
Attorney Docket No. P-022-US5
Request for a Corrected Filing Receipt
Page 2

A Corrected Filing Receipt is respectfully requested.

Should there be any questions concerning this request or any other issues, the USPTO is encouraged to contact the undersigned agent at (650) 808-6144.

Respectfully submitted,
THERAVANCE, INC.

Date: July 19, 2004

By: Joyce Cohen
Joyce Cohen, Reg. No. 44,622.

THERAVANCE, INC.
901 Gateway Blvd.
South San Francisco, CA 94080
Telephone: (650) 808-6000
Fax: (650) 808-6078



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY SCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/825,038	04/15/2004	1646	385	7-022-US5		8	2

27038
THERAVANCE, INC.
901 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080

RECEIVED

JUL 06 2004

THERAVANCE, INC.
LEGAL DEPARTMENT

CONFIRMATION NO. 7371

FILING RECEIPT



OC000000013095999

Date Mailed: 06/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Martin S. Linsell, San Mateo, CA;

Domestic Priority data as claimed by applicant

This application is a CON of 10/092,088 03/06/2002
which is a CON of 09/470,209 12/22/1999 PAT:6,392,012
which claims benefit of 60/113,728 12/23/1998
and claims benefit of 60/129,313 04/14/1999
and claims benefit of 60/164,024 11/04/1999
and claims benefit of 60/169,978 12/10/1999

Foreign Applications

If Required, Foreign Filing License Granted: 06/28/2004

Projected Publication Date: 10/07/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

BEST AVAILABLE COPY

*Intermediate for preparing**^* Glycopeptide derivatives and pharmaceutical compositions containing the same.

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations; 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).